Canadian Halal Investor.

NYSE Shariah screener · October 2026

Is Haleon plc (HLN) Halal?

PASS

Haleon plc · NYSE: HLN · Consumer Staples

The short answer

Haleon passes all three Shariah gates: its consumer health business (Sensodyne, Advil, Panadol, Centrum and others) involves no prohibited activities, its interest-bearing debt of £8.48B is 29.2% of its ~$38.35 billion market cap (under the 33% ceiling), and interest income of 0.52% of revenue is far under the 5% ceiling.

Gate 1 — Business activity: PASS

Gate 1 — business activity: PASS. Haleon plc is a consumer health company spun off from the GSK/Pfizer joint venture and listed in July 2022, headquartered in Weybridge, UK. Per its FY2025 Form 20-F (filed with the SEC March 13, 2026), its product portfolio spans six major categories — Oral Health, Vitamins Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other — with long-standing brands including Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren, sold to more than a billion consumers worldwide.

The company is not an interest-based lender and is not involved in alcohol, tobacco, gambling, pork, adult entertainment or weapons. None of its reported categories involves a prohibited activity, so the business passes gate 1.

Gate 2 — Debt and cash: PASS

Gate 2 — interest-bearing debt: PASS (29.2%, ceiling 33%). Haleon's FY2025 Form 20-F (Note 19, Borrowings) reports total borrowings of £8,609 million at December 31, 2025 — comprising bonds (£8,102 million), loans and overdrafts (£343 million), advances (£6 million) and non-voting preference shares (£25 million). Lease liabilities (£133 million: £48 million current plus £85 million non-current) are excluded — IFRS 16 lease obligations are not interest-bearing debt. That leaves £8,476 million of interest-bearing debt, about $11.2 billion at the GBP/USD rate of 1.321 (Finnhub, October 2, 2026).

$11.2 billion of interest-bearing debt against a market capitalization of about $38.35 billion (Finnhub live price $8.72 per ADR on October 2, 2026 × 4,398,270,000 ADRs outstanding per MarketBeat) is 29.2%, under the 33% ceiling. Cash and cash equivalents of £1,324 million at December 31, 2025 (Note 17) represent about 4.6% of market cap.

Gate 3 — Non-compliant income: PASS

Gate 3 — non-compliant income: PASS (0.52%, ceiling 5%). Haleon's FY2025 Form 20-F separately discloses interest income in Note 8 (Net finance costs): "Interest income on financial assets at amortised cost: Cash and cash equivalents" of £57 million in 2025 (2024: £65 million, 2023: £25 million). FY2025 interest income of £57 million against FY2025 total revenue of £11,030 million is about 0.52%, far under the 5% ceiling.

Note: the H1 2026 half-year results (published July 30, 2026 via Form 6-K) do not separately break out interest income — they report only "Finance income" of £34 million and "Finance expense" of £153 million for the six months ended June 30, 2026 — so the verified FY2025 figure from the 20-F is used for this gate.

Key figures used

Frequently asked questions

What does Haleon do?

Haleon plc is a UK consumer health company that develops, manufactures and sells over-the-counter health products across six major categories: Oral Health, Vitamins Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other. Its portfolio includes well-known brands such as Sensodyne, Advil, Panadol, Voltaren, Centrum, Otrivin, Theraflu, Polident and parodontax, sold in markets across North America, Europe, the Middle East, Africa, Latin America and Asia Pacific. The company was spun off from the GSK and Pfizer consumer health joint venture and listed in July 2022, employing about 24,000 people. Its ordinary shares trade on the London Stock Exchange and its American Depositary Shares (each representing two ordinary shares) trade on the New York Stock Exchange under the ticker HLN.

Is Haleon's business Shariah compliant?

Haleon's business is consumer health products - toothpaste and mouthwash (Sensodyne, parodontax), pain relievers (Advil, Panadol, Voltaren), vitamins and supplements (Centrum), and respiratory and digestive remedies (Otrivin, Theraflu). It is not an interest-based lender and is not involved in alcohol, tobacco, gambling, pork or weapons. None of its six reported product categories raises a Shariah business-activity concern, so the business passes this screener's first gate.

How much interest-bearing debt does Haleon have?

Haleon's FY2025 Form 20-F (Note 19, Borrowings) reports total borrowings of 8,609 million pounds at December 31, 2025 - mostly bonds (8,102 million pounds), plus loans and overdrafts (343 million pounds), advances (6 million pounds) and non-voting preference shares (25 million pounds). Lease liabilities of 133 million pounds are excluded, as IFRS 16 lease obligations are not interest-bearing debt for this screener. That leaves 8,476 million pounds of interest-bearing debt, or about 11.2 billion US dollars at the GBP/USD rate of 1.321 (Finnhub, October 2, 2026). Against a market capitalization of about 38.35 billion dollars (8.72 dollars per ADR times 4,398,270,000 ADRs outstanding, per MarketBeat), that is 29.2%, under the 33% ceiling. Cash and cash equivalents of 1,324 million pounds at December 31, 2025 represent about 4.6% of market cap.

How much interest income does Haleon earn?

Haleon's FY2025 Form 20-F separately discloses interest income in Note 8 (Net finance costs): 'Interest income on financial assets at amortised cost: Cash and cash equivalents' of 57 million pounds in 2025 (65 million pounds in 2024 and 25 million pounds in 2023). Against FY2025 revenue of 11,030 million pounds, the 57 million pounds of interest income is about 0.52% - far under the 5% non-compliant income ceiling.

What do third-party Shariah screeners say about Haleon?

Zoya publishes a dedicated Haleon (HLN) page; its published figures show interest income of 76,290,663 pounds against revenue of 11,030,000,000 pounds (0.69%), consistent with a compliant read, though its current rating was not verifiable from the publicly fetched page text. Musaffa publishes an HLN stock page and, as of October 2026, classifies Haleon plc as halal under its AAOIFI-based Shariah screening methodology. I could not verify a ShariaPortfolio rating page for HLN from public sources. Third-party screeners apply different assumptions and update on different schedules, and their results can change when new financial statements are published - always check the latest screening before investing.

Sources

Screened 2026-10-02 from published company figures and market data. Figures change; this page is educational, not financial advice and not a religious ruling.

Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).